Justin R Bailey1, Kimberly A Dowd2, Anna E Snider1, William O Osburn1, Shruti H Mehta3, Gregory D Kirk4, David L Thomas1, Stuart C Ray5. 1. Division of Infectious Diseases, Department of Medicine. 2. Viral Pathogenesis Section, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland. 3. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore. 4. Division of Infectious Diseases, Department of Medicine Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore. 5. Division of Infectious Diseases, Department of Medicine Department of Oncology, Johns Hopkins University School of Medicine.
Abstract
BACKGROUND: Human immunodeficiency virus (HIV) infection leads to lower rates of hepatitis C virus (HCV) clearance after acute infection, higher HCV viremia, and accelerated progression of HCV-related fibrosis. The mechanisms underlying this acceleration of HCV progression by HIV are poorly understood, but HIV-induced dysfunction in the anti-HCV humoral immune response may play a role. METHODS: To define the effect of HIV coinfection on the anti-HCV antibody response, we measured anti-HCV envelope binding antibody titers, neutralizing antibody (nAb) titers, and nAb breadth of serum from HCV-infected subjects isolated longitudinally before and after incident HIV infection. RESULTS: A significant reduction in HCV envelope-specific binding antibody and nAb titers was detected in subjects with CD4(+) T-cell counts <350/mm(3) after HIV infection, and subjects with CD4(+) T-cell counts <200/mm(3) also showed a reduction in nAb breadth. Subjects who maintained CD4(+) T-cell counts ≥350/mm(3) displayed little to no decline in antibody levels. CONCLUSIONS: Depletion of CD4(+) T cells by HIV infection results in a global decline in the anti-HCV envelope antibody response, including binding antibody titers, nAb titers, and nAb breadth.
BACKGROUND: Human immunodeficiency virus (HIV) infection leads to lower rates of hepatitis C virus (HCV) clearance after acute infection, higher HCV viremia, and accelerated progression of HCV-related fibrosis. The mechanisms underlying this acceleration of HCV progression by HIV are poorly understood, but HIV-induced dysfunction in the anti-HCV humoral immune response may play a role. METHODS: To define the effect of HIV coinfection on the anti-HCV antibody response, we measured anti-HCV envelope binding antibody titers, neutralizing antibody (nAb) titers, and nAb breadth of serum from HCV-infected subjects isolated longitudinally before and after incident HIV infection. RESULTS: A significant reduction in HCV envelope-specific binding antibody and nAb titers was detected in subjects with CD4(+) T-cell counts <350/mm(3) after HIV infection, and subjects with CD4(+) T-cell counts <200/mm(3) also showed a reduction in nAb breadth. Subjects who maintained CD4(+) T-cell counts ≥350/mm(3) displayed little to no decline in antibody levels. CONCLUSIONS: Depletion of CD4(+) T cells by HIV infection results in a global decline in the anti-HCV envelope antibody response, including binding antibody titers, nAb titers, and nAb breadth.
Authors: Annelies S Zinkernagel; Viktor von Wyl; Bruno Ledergerber; Martin Rickenbach; Hansjakob Furrer; Manuel Battegay; Bernard Hirschel; Philip E Tarr; Milos Opravil; Enos Bernasconi; Patrick Schmid; Rainer Weber Journal: Antivir Ther Date: 2006
Authors: Sukanya Raghuraman; Heiyoung Park; William O Osburn; Emily Winkelstein; Brian R Edlin; Barbara Rehermann Journal: J Infect Dis Date: 2012-01-31 Impact factor: 5.226
Authors: Rainer Weber; Caroline A Sabin; Nina Friis-Møller; Peter Reiss; Wafaa M El-Sadr; Ole Kirk; Francois Dabis; Matthew G Law; Christian Pradier; Stephane De Wit; Börje Akerlund; Gonzalo Calvo; Antonella d'Arminio Monforte; Martin Rickenbach; Bruno Ledergerber; Andrew N Phillips; Jens D Lundgren Journal: Arch Intern Med Date: 2006 Aug 14-28
Authors: Antonio Petrarca; Luigi Rigacci; Patrizio Caini; Stefano Colagrande; Paolo Romagnoli; Francesco Vizzutti; Umberto Arena; Carlo Giannini; Monica Monti; Paolo Montalto; Marco Matucci-Cerinic; Alberto Bosi; Giacomo Laffi; Anna Linda Zignego Journal: Blood Date: 2010-03-22 Impact factor: 22.113
Authors: Zhen-yong Keck; Jinming Xia; Yong Wang; Wenyan Wang; Thomas Krey; Jannick Prentoe; Thomas Carlsen; Angela Ying-Jian Li; Arvind H Patel; Stanley M Lemon; Jens Bukh; Felix A Rey; Steven K H Foung Journal: PLoS Pathog Date: 2012-04-12 Impact factor: 6.823
Authors: Stuart C Ray; Liam Fanning; Xiao-Hong Wang; Dale M Netski; Elizabeth Kenny-Walsh; David L Thomas Journal: J Exp Med Date: 2005-06-06 Impact factor: 14.307
Authors: Jannie van der Helm; Ronald Geskus; Caroline Sabin; Laurence Meyer; Julia Del Amo; Geneviève Chêne; Maria Dorrucci; Roberto Muga; Kholoud Porter; Maria Prins Journal: Gastroenterology Date: 2012-12-22 Impact factor: 22.682
Authors: Lisa N Wasilewski; Ramy El-Diwany; Supriya Munshaw; Anna E Snider; Jillian K Brady; William O Osburn; Stuart C Ray; Justin R Bailey Journal: J Virol Date: 2016-01-27 Impact factor: 5.103
Authors: Ruth S Mwatelah; Raphael M Lwembe; Saida Osman; Bernhards R Ogutu; Rashid Aman; Rose C Kitawi; Laura N Wangai; Florence A Oloo; Gilbert O Kokwaro; Washingtone Ochieng Journal: PLoS One Date: 2015-07-24 Impact factor: 3.240
Authors: Yong-Hong Zhang; Yan Zhao; Ushani S Rajapaksa; Tessa M Lawrence; Yan-Chun Peng; Jinghua Liu; Keyi Xu; Ke Hu; Ling Qin; Ning Liu; Huanqin Sun; Hui-Ping Yan; Emmanouela Repapi; Sarah Rowland-Jones; Robert Thimme; Jane A McKeating; Tao Dong Journal: PLoS One Date: 2016-07-25 Impact factor: 3.240